Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from Pieris Pharmaceuticals (PIRS).
Pieris Pharmaceuticals, Inc. has received a notice from Les Laboratoires Servier to terminate their collaborative agreement on Anticalin-based therapeutics due to safety concerns from a Phase 1 clinical study. This termination will also end the associated Non-Exclusive License Agreement, effective December 27, 2024. Despite this setback, Pieris Pharmaceuticals still has the potential to earn significant milestones and royalties through other partnerships, with possible milestone payments reaching up to $200 million and commercial milestones over $415 million for its 4-1BB bispecific Mabcalin protein assets, developed with Boston Pharmaceuticals and Pfizer Inc. The company is also exploring strategic opportunities to enhance stockholder value.
See more data about PIRS stock on TipRanks’ Stock Analysis page.
